MetLife, Inc. (MET) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is mixed-to-cautious — consensus is a manageable bar, but the single biggest swing factor is whether variable investment income (VII) comes in at the low end of management's pre-announced $220–$270M range and whether the non-medical health benefit ratio shows the second-half improvement management guided for.

Bar: Consensus adjusted EPS for Q2 2026 stands at $2.34 (Visible Alpha), down from $2.54 at the post-Q1 baseline (May 8, 2026) — a meaningful ~8% downward revision over the inter-quarter period, driven primarily by the June 29 pre-announcement that Q2 VII would land at approximately $220–$270M pre-tax, well below the ~$400M quarterly run-rate management had guided and the $518M Q1 2026 actual. The bar is therefore already reset lower, reducing the risk of a miss on the headline EPS line.

Guidance/Tone: Management's posture has shifted modestly more cautious on VII and the non-medical health benefit ratio since the Q1 call. At the June 2026 Morgan Stanley U.S. Financials Conference, CFO John McCallion acknowledged Q2 would see "a little more pressure" on VII given how Q1 closed, while expressing optimism about Q3 given the IPO market recovery and VC portfolio positioning. On Group Benefits, management expects the non-medical health benefit ratio (75.8% in Q1, above the 70–75% annual target) to moderate — but only in the second half of the year, implying Q2 may still be elevated. Tone on Latin America ($1B earnings target now described as "real for '26"), EMEA, Asia, and MIM integration remains constructive.

Estimate Trajectory: Estimates have drifted lower since Q1 earnings — Q2 2026 adjusted EPS consensus fell from $2.54 (May 8) to $2.34 (August 4), a ~8% decline, almost entirely attributable to the VII pre-announcement. Full-year 2026 EPS consensus moved from $10.28 to $9.89 over the same period. The gap between current consensus and the pre-announcement VII range is now well-understood by the Street, suggesting limited incremental downside from VII alone. The key risk/cushion is whether Group Benefits morbidity (mortality favorable, non-medical health elevated) and MIM earnings trajectory surprise in either direction.

Stock Setup: MET has rallied approximately +20% since the Q1 2026 earnings date (May 6), significantly outperforming both the insurance sector ETF (KIE, +15%) and the S&P 500 (+3%). The stock trades at ~9.2x NTM P/E — still at a discount to historical averages — suggesting the multiple has expanded but is not stretched. The rally appears driven by a combination of multiple re-rating and improving earnings expectations under the New Frontier strategy, though the recent VII pre-announcement caused some consolidation. The stock is not pricing in a large beat, but the elevated price level means any disappointment on Group Benefits or MIM could trigger a pullback.

Wildcard: The single biggest wildcard is the non-medical health interest-adjusted benefit ratio. Management guided for second-half improvement but expressed uncertainty about whether the Q1 elevation (driven by dental seasonality, disability severity, and new state-mandated paid family leave programs) is a Q1 phenomenon or a first-half/second-half dynamic. Peer commentary from Unum (UNM) confirms that PFML-driven disability claims remain elevated industry-wide in Q2, with UNM's own disability benefit ratio coming in above expectations at 65.8% vs. a 62–64% target. If MET's non-medical health ratio remains near Q1's 75.8% rather than moderating, it would be a meaningful negative surprise relative to the 70–75% annual target.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low bar on adjusted EPS given the VII pre-announcement reset, but the non-medical health benefit ratio is the bigger swing factor — any further elevation above the 70–75% annual target would be a negative surprise, while a return toward the midpoint of the range would be a positive catalyst.

Table 1 — Current Quarter Snapshot (Q2 2026 Key KPIs)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of August 4, 2026. Q1 2026 and Q2 2025 actuals from Visible Alpha. MIM Q2 2025 actual reflects reported segment earnings. VII Q2 2026 estimate reflects midpoint of management's June 29, 2026 pre-announcement range of $220–$270M pre-tax.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

KPI 1: Adjusted EPS (Diluted, excl. notable items)

Pattern: MET has beaten on adjusted EPS in 3 of the last 4 quarters, with the two misses (Q3 2024, Q2 2025) both driven by below-expectation variable investment income. The Q1 2026 beat was driven by above-expectation VII and favorable Group Life mortality. With VII already pre-announced at the low end of the quarterly run-rate, the Q2 2026 beat/miss will hinge on underwriting results.

KPI 2: Non-Medical Health Interest-Adjusted Benefit Ratio (Group Benefits, %)

Pattern: The non-medical health benefit ratio has missed (come in above) consensus in 5 of the last 8 quarters, reflecting persistent pressure from dental utilization, disability severity, and more recently, new state-mandated paid family leave programs. The ratio has been above the 70–75% annual target in 4 of the last 5 quarters. Consensus for Q2 2026 at 74.3% implies modest improvement from Q1's 75.8% but remains near the top of the target range.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: The most significant post-Q1 guidance update was the June 29 pre-announcement of Q2 variable investment income at $220–$270M pre-tax — well below the ~$400M quarterly run-rate — which drove the bulk of the inter-quarter estimate revision. All other guidance metrics remain unchanged from the Q1 2026 earnings call.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been revised sharply lower since Q1 earnings, almost entirely driven by the June 29 VII pre-announcement. The gap between current consensus and the pre-Q1 baseline is now well-understood by the Street. Full-year 2026 EPS consensus has declined ~3.8% from the post-Q1 baseline, but remains above the pre-Q1 level, reflecting the strong Q1 beat. The key question is whether Q3 VII recovery (management guided constructively) will allow full-year estimates to recover.

Source: Visible Alpha Consensus and Actuals Data. Post-Q1 baseline = consensus as of May 8, 2026 (5 trading days after Q1 2026 earnings release on May 6, 2026). Current consensus as of August 4, 2026.

Commentary: The estimate revision story is almost entirely a VII story. The June 29 pre-announcement crystallized the Q2 VII shortfall, and the Street has adjusted accordingly. The more interesting question for the print is whether Group Benefits morbidity (non-medical health ratio) shows any improvement from Q1's elevated 75.8%, and whether MIM earnings continue to ramp post-PineBridge integration. Management's constructive tone on Q3 VII (IPO market recovery, VC portfolio positioning) suggests the full-year $1.6B guidance is achievable, but requires a meaningful Q3/Q4 recovery.

5. Stock Performance

Key Takeaway: MET's +20% rally since Q1 2026 earnings has been driven by a combination of multiple expansion and improving earnings expectations under the New Frontier strategy — the stock has significantly outperformed both the insurance sector (KIE +15%) and the S&P 500 (+3%). The VII pre-announcement caused a brief consolidation but the stock has held its gains, suggesting the market views the Q2 VII shortfall as transitory.

MET vs. KIE (Insurance ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (May 6, 2026). Source: Yahoo Finance / Stock Price Data.

Sector ETF: KIE (SPDR S&P Insurance ETF) — tracks the S&P Insurance Select Industry Index, which includes life, P&C, and multi-line insurers. Appropriate for MET's sub-sector as a diversified life/group benefits insurer.

Key Events Since Q1 2026 Earnings (May 6, 2026):

• May 6–7, 2026: Q1 2026 earnings beat — adjusted EPS $2.42 vs. $2.27 consensus (+6.6%); stock closed modestly higher, muted reaction suggesting results were largely in line with elevated expectations.
• June 10, 2026: Morgan Stanley U.S. Financials Conference — CFO McCallion provided constructive forward guidance on LatAm ($1B target "real for '26"), MIM integration, and Q3 VII outlook. Stock continued to rally.
• June 29, 2026: MetLife pre-announced Q2 2026 VII at $220–$270M pre-tax (8-K filing) — well below the ~$400M quarterly run-rate. Stock consolidated but held most gains.
• July 9, 2026: MetLife announced Q2 2026 earnings release scheduled for August 5, 2026 (earnings call August 6, 2026).

Performance Summary (May 6 – August 4, 2026):

Source: Yahoo Finance / Stock Price Data. Prices are closing prices.

Valuation Context: MET currently trades at ~9.2x NTM P/E (vs. ~7.9x at the Q1 2026 earnings date), reflecting ~16% multiple expansion over the period. The stock also trades at 1.48x P/Book (NTM) and 0.73x EV/Sales. Despite the re-rating, MET remains at a discount to historical averages, suggesting the market has not fully priced in the improved earnings power under the New Frontier strategy. The 12-month price performance of +29.9% has been driven roughly equally by earnings growth and multiple expansion.

Source: Stock Performance Decomposition Data.

6. Peer Commentaries — Q2 2026 Current-Quarter Read-Throughs

Key Takeaway: Peer Q2 2026 earnings provide a broadly constructive read-through for MET on mortality (favorable industry-wide), retirement/annuity demand (strong), and asset management flows (positive market tailwinds). The key negative read-through is from Unum (UNM), which confirms that PFML-driven disability claims remain elevated in Q2 — directly relevant to MET's non-medical health benefit ratio. Prudential's Japan sales suspension is company-specific and not a read-through for MET.

Note on Scope: All commentary below reflects Q2 2026 results and forward-looking statements made by peers during their Q2 2026 earnings calls and releases (July–August 2026). Prior-quarter results commentary (e.g., Q1 2026 results discussed on Q1 calls) is excluded per the user's instruction. Only current-quarter (Q2 2026) observations and forward guidance relevant to MET's upcoming print are included.

Unum Group (UNM) — Q2 2026 Earnings (July 28–29, 2026)

Relevance to MET: Very High. UNM is the most direct read-through for MET's Group Benefits segment, particularly disability and group life. Both companies have significant U.S. group disability and life insurance operations.

• PFML-Driven Disability Pressure Persists in Q2: UNM's Q2 2026 group disability benefit ratio came in at 65.8%, above its 62–64% target, with approximately 60–70% of the elevation driven by higher claims activity in newer Paid Family and Medical Leave (PFML) markets. UNM is active in 13 PFML states and has begun implementing double-digit rate adjustments. Read-through for MET: MET's Q1 2026 non-medical health benefit ratio was elevated at 75.8% (above the 70–75% target), with management citing PFML-related paid family leave strain as a contributor. UNM's Q2 data confirms that PFML pressure is an industry-wide Q2 phenomenon, not just a Q1 issue for MET. This increases the risk that MET's Q2 non-medical health ratio remains elevated rather than moderating toward the target range.
• Favorable Group Life Mortality Continues: UNM's Q2 2026 group life and AD&D benefit ratio improved to 66.0% from 69.7% in Q2 2025, driven by "continued lower incidents" and favorable mortality trends. Management expects this to continue. Read-through for MET: Positive. MET's Q1 2026 Group Life mortality ratio was exceptional at 80.1% (well below the 83–88% target). UNM's Q2 data confirms that favorable working-age population mortality is an industry-wide trend continuing into Q2 2026.
• U.K. Group Income Protection Pressure: UNM's U.K. segment benefit ratio rose to 78.4% from 72.4% in Q2 2025, driven by elevated average claim values from high-income employees. UNM expects continued pressure in H2 but at lower levels. Read-through for MET: Moderate. MET has international group benefits operations including in the U.K. Similar demographic claim patterns could affect MET's EMEA segment, though EMEA is primarily protection-oriented and has shown strong growth.
• LTC Reinsurance Activity: UNM announced an agreement to reinsure an additional $3.8B of LTC statutory reserves (Fortitude Re transaction), representing ~26% of its total LTC block. Read-through for MET: Indirect. MET has legacy LTC exposure in MetLife Holdings and has expressed openness to value-accretive LTC risk transfer transactions. UNM's continued progress in this market validates the availability of reinsurance capacity.
• Premium Growth and Persistency Strong: UNM reported underlying premium growth of ~5%, with U.S. group persistency at 91.5% (up ~2 ppts YoY). U.S. Unum brand sales grew 7.4% in Q2, with year-to-date sales growth of 14%. Read-through for MET: Positive. Suggests healthy demand environment for group benefits products that MET also offers.

Lincoln National (LNC) — Q2 2026 Earnings (July 30, 2026)

Relevance to MET: High. LNC has significant group benefits, annuities, and life insurance operations. Particularly relevant for MET's Group Benefits disability trends, mortality, and retirement/annuity spreads.

• Disability Normalization (Not PFML-Driven): LNC's Q2 2026 group disability loss ratio was 71.9%, up from 64.2% in Q2 2025, reflecting normalization from exceptionally favorable LTD results in 2025. Importantly, LNC noted that PFML impact in Q2 was less than 20 bps (vs. ~100 bps in Q1 2026), indicating the PFML headwind is primarily a Q1 dynamic for LNC. Read-through for MET: Mixed. LNC's data suggests PFML impact may be diminishing in Q2 for some carriers, but UNM's data (above) shows it remains elevated for others. The net read-through for MET is uncertain — the PFML impact on MET's Q2 ratio will depend on its specific state exposure and product mix.
• Favorable Mortality Across Life Insurance: LNC's Q2 2026 life loss ratio improved ~500 bps YoY to ~62%, with "broad-based favorability across both frequency and severity" described as "among the most favorable results we have seen in some time." Management noted 5 of the last 6 quarters have been favorable for mortality. Read-through for MET: Positive. Confirms industry-wide favorable mortality trend continuing into Q2 2026, supporting MET's Group Life mortality ratio remaining below the 83–88% target.
• Alternative Investment Returns Below Target: LNC's alternative investment portfolio delivered an annualized return of ~5% in Q2 2026, below its 10% annualized target, representing $43M after-tax of below-target income. However, LNC expects alternative returns to improve meaningfully in Q3 based on visibility into public and VC positions. Read-through for MET: Consistent with MET's own VII pre-announcement. LNC's Q3 optimism on alternatives aligns with MET management's constructive tone on Q3 VII at the Morgan Stanley Conference.
• Annuity Sales Mix Shift to Spread-Based Products: LNC's total annuity sales were $3.5B in Q2, with spread-based products representing 63% of sales. RILA sales rose 10% YoY. Fixed annuity sales were lower but LNC remains bullish on the category. RPS base spreads were 119 bps, up 20 bps YoY. Read-through for MET: Positive for MET's RIS segment. Strong demand for spread-based retirement products and improving spreads support MET's RIS earnings trajectory.
• GUL Reinsurance Transaction: LNC announced an agreement with Talcott to reinsure ~$6B of legacy GUL reserves (~37% of remaining GUL block), expected to close in Q4 2026. Read-through for MET: Indirect. MET has legacy life reserves in MetLife Holdings. LNC's transaction validates the availability of reinsurance capacity for legacy life blocks.

Principal Financial Group (PFG) — Q2 2026 Earnings (July 27, 2026)

Relevance to MET: High. PFG has significant group benefits (Specialty Benefits), retirement (RIS), and asset management operations. Particularly relevant for MET's Group Benefits morbidity, mortality, and retirement/annuity trends.

• Group Benefits (Specialty Benefits) Outperformance: PFG's Specialty Benefits segment reported a Q2 2026 incurred loss ratio of 57.4%, below its targeted range and improved from 60.2% in Q2 2025. Operating margin improved 300 bps. Sales were up 11% YoY. Read-through for MET: Positive. PFG's strong group benefits performance suggests a favorable underwriting environment. However, PFG's product mix (smaller employer focus) differs from MET's large-group orientation, so the read-through is directional rather than precise.
• Improved Mortality in Life Insurance: PFG's Life Insurance segment reported a 26% increase in pre-tax operating earnings, driven by "improved mortality experience." Operating margin improved 280 bps. Read-through for MET: Positive. Confirms industry-wide favorable mortality trend in Q2 2026.
• RIS Strong with Higher Net Investment Spread: PFG's RIS segment reported a 30% increase in transfer deposits ($9B), with operating margin improving 60 bps. Net revenue grew 9% driven by "favorable market performance and growth in the business." Higher than expected variable investment income in RIS was noted as a positive variance. Read-through for MET: Positive for MET's RIS segment. Strong retirement product demand and favorable market conditions support MET's RIS earnings.
• Variable Investment Income Mixed Across Segments: PFG noted lower than expected VII in International Pension, Specialty Benefits, and Life Insurance, partially offset by higher than expected VII in RIS and Corporate. Read-through for MET: Consistent with MET's own VII pre-announcement. The mixed VII performance across PFG's segments aligns with the broader alternative investment environment in Q2.
• Asset Management Net Outflows: PFG's Investment Management segment reported AUM net cash flow of negative $11.1B in Q2 2026 (vs. negative $2.6B in Q2 2025), despite AUM growing 7% to $808B due to market appreciation. Read-through for MET: Cautionary for MIM. PFG's significant net outflows despite market appreciation suggest that institutional asset managers are facing headwinds in retaining client assets. MIM experienced ~$2B in institutional outflows in Q1 2026 due to PineBridge integration; Q2 outflow trends will be closely watched.

Prudential Financial (PRU) — Q2 2026 Earnings (August 4, 2026)

Relevance to MET: High. PRU is the most direct large-cap life insurance peer to MET, with similar diversified operations across group insurance, retirement, individual life, and international businesses.

• Strong Overall Results: PRU reported Q2 2026 after-tax adjusted operating income of $1.438B ($4.08/share), up from $1.284B ($3.58/share) in Q2 2025. Net income was $985M ($2.80/share), up from $533M ($1.48/share). Parent company highly liquid assets increased to $4.2B. Read-through for MET: Positive. Strong overall financial performance from PRU suggests a favorable operating environment for large diversified insurers in Q2 2026.
• Favorable Group Insurance Mortality: PRU's Group Insurance segment reported adjusted operating income of $155M (up from $125M in Q2 2025), driven by "more favorable mortality in the working-age population in life underwriting results and higher net investment spread results." Year-to-date sales increased 26%, driven by strong disability product sales. Read-through for MET: Positive. Confirms favorable working-age mortality and strong disability sales demand — directly relevant to MET's Group Benefits segment.
• PGIM Asset Management: Positive Flows and AUM Growth: PGIM reported adjusted operating income of $294M (up from $229M in Q2 2025), driven by higher asset management fees from equity market appreciation and strong investment performance. Total net inflows were $1.6B, with third-party institutional net inflows of $3.1B (public and private credit inflows partially offset by public equity outflows). AUM grew 4% to $1.491T. Read-through for MET: Positive for MIM. PGIM's positive net flows and AUM growth driven by favorable market conditions suggest a constructive environment for institutional asset managers. The shift toward private credit inflows is consistent with MIM's private assets focus.
• Retirement Segment: Higher Spreads, Strong Annuity Sales: PRU's Retirement segment reported adjusted operating income of $392M (essentially unchanged from $397M in Q2 2025). Net account values grew 4% to $363B. Total sales were $6.8B, including $3.6B of retail annuity sales with "continued strong momentum" from the December 2025 RILA product launch. Higher net investment spread results were noted. Read-through for MET: Positive for MET's RIS segment. Strong retail annuity demand and improving spreads support MET's retirement earnings.
• Japan Sales Suspension — Company-Specific: PRU's International Businesses reported a 33% decline in constant dollar sales, primarily driven by the Prudential of Japan sales suspension related to employee misconduct remediation. Management noted the suspension may continue longer than expected. Read-through for MET: Not a direct read-through. MET's Japan operations are navigating a separate industry-wide FSA regulatory matter (improper data extraction by seconded employees at partner agencies), which management characterized as having no material business impact. PRU's Japan issue is company-specific and more severe.
• International Business Growth (ex-Japan): PRU's International Businesses (ex-Japan) showed higher net investment spread results, higher joint venture earnings, and business growth in Brazil. Read-through for MET: Positive for MET's Latin America and Asia segments. Favorable international operating conditions support MET's LatAm $1B earnings target and Asia growth momentum.

Equitable Holdings (EQH) — Q2 2026 Earnings (August 4, 2026)

Relevance to MET: Moderate. EQH's primary businesses are retirement/annuities and asset management (AllianceBernstein). Less relevant for Group Benefits, mortality, or Asia/Japan, but provides read-through for retirement product demand and asset management flows.

• Retirement Segment Strong: EQH's Retirement segment reported net inflows of $1.7B and first-year premiums of $6.2B (up 13% YoY). Operating earnings increased to $402M from $354M, driven by higher fee-based revenue and a lower tax rate. Total assets grew 15% to $188.8B. Read-through for MET: Positive for MET's RIS segment. Strong retirement product demand and net inflows suggest a healthy environment for institutional retirement solutions.
• AllianceBernstein (AB) Asset Management: Positive Flows: AB reported net inflows of $0.8B in Q2, driven by retail ($0.9B) and institutional ($0.6B) channels, partially offset by private wealth outflows ($0.7B). Total AUM/A grew 10% YoY to a record $1.2T, driven by positive net flows and higher markets. Operating earnings increased to $158M from $131M, driven by growth in base fees. Read-through for MET: Positive for MIM. EQH's positive asset management flows and AUM growth driven by favorable market conditions suggest a constructive environment for MIM's third-party business.
• Lower Net Investment Income from Alternatives: EQH noted lower net investment income from alternatives as a notable item in the Retirement segment. Read-through for MET: Consistent with MET's VII pre-announcement. Confirms that alternative investment returns were below expectations across the industry in Q2 2026.
• Merger with Corebridge Financial: EQH's merger with Corebridge Financial was approved by shareholders on July 30 and is on track to close by year-end 2026. Read-through for MET: Not a direct read-through for Q2 results. Highlights ongoing consolidation in the life insurance sector.

Globe Life (GL) — Q2 2026 Earnings (July 22–23, 2026)

Relevance to MET: Low-to-Moderate. GL is primarily a direct-to-consumer life and health insurer with a different distribution model and product mix than MET. Read-throughs are directional rather than precise.

• Favorable Life Mortality: GL's life policy obligations as a percent of premium improved from 36.7% in Q2 2025 to 34.3% in Q2 2026, described as "consistent with the continued favorable trends in mortality." Read-through for MET: Positive. Confirms broad-based favorable mortality trend across the industry in Q2 2026.
• Health Obligations Above Estimates: GL's health obligations as a percent of premium increased to 56.8% from 53.3% in Q2 2025, above estimates. Drivers included Medicare supplement claims related to prior periods (including an industry-wide CMS physician reimbursement rate correction), adverse fluctuation in high-severity claims, and cancer claims at Liberty National. GL expects claims experience to moderate for the remainder of the year. Read-through for MET: Cautionary. The industry-wide CMS physician reimbursement rate correction could affect MET's health-related businesses if it has exposure to Medicare supplement or related health lines. However, MET's Group Benefits is primarily employer-sponsored, so the direct impact may be limited.
• AI Impact on Digital Marketing: GL noted that increased utilization of AI by consumers has resulted in a reduction in paid search volume from internet marketing, impacting its direct-to-consumer (DTC) division. Net life sales in DTC were down 15% YoY. GL is implementing initiatives to adapt. Read-through for MET: Indirect. MET's distribution is primarily employer-sponsored and agent-based, so the DTC digital marketing impact is less relevant. However, the broader AI-driven shift in consumer behavior is a theme MET is also navigating.
• New Money Investment Yields Strong: GL invested $399M in fixed maturities in Q2 at an average yield of 6.27% (A-rated, 36-year average life). Expects to invest at 6.0–6.1% for the remainder of 2026. Read-through for MET: Positive. Confirms that new money yields remain attractive for insurance company investment portfolios, supporting MET's core investment income (ex-VII).

Summary Read-Through Table

7. Material News & Developments

Key Takeaway: The most important development since Q1 2026 earnings is the June 29 VII pre-announcement, which reset Q2 EPS expectations lower and is now fully reflected in consensus. The Morgan Stanley Conference (June 10) provided constructive forward guidance on LatAm, MIM, and Q3 VII. No material negative regulatory or legal developments have emerged for MET specifically.

• June 29, 2026 — Q2 VII Pre-Announcement (8-K): MetLife pre-announced Q2 2026 variable investment income at approximately $220–$270M pre-tax, compared to the full-year 2026 guidance of approximately $1.6B pre-tax. This compares to the ~$400M quarterly run-rate and the $518M Q1 2026 actual. The pre-announcement drove a ~8% downward revision in Q2 EPS consensus and a ~4% revision in FY2026 EPS consensus. Implication: The bar is now reset; the key question is whether Q3 VII recovers as management expects.
• June 10, 2026 — Morgan Stanley U.S. Financials Conference: CFO John McCallion provided constructive forward guidance: (1) Latin America's $1B annual earnings target is "real for '26," supported by Accelerator platform sales growing from $200M to $700M in ~1 year; (2) Q3 VII setup described as "very well" given IPO market recovery and VC portfolio positioning; (3) MIM integration with PineBridge progressing better than anticipated; (4) RIS spreads expected to remain range-bound near 95 bps ex-VII absent yield curve steepening; (5) private fixed income portfolio is 95% investment grade with minimal middle-market direct lending and no BDC exposure. Implication: Constructive tone on multiple fronts; key positive catalyst if Q3 VII recovery materializes.
• June 22, 2026 — Annual Shareholder Meeting: MetLife shareholders affirmed governance and compensation at the 2026 Annual Meeting (8-K filing). No material governance changes.
• July 9, 2026 — Q2 2026 Earnings Date Announcement: MetLife announced Q2 2026 results scheduled for August 5, 2026 (earnings call August 6, 2026 at 9:00 AM ET).
• Ongoing — Japan FSA Regulatory Matter: MetLife Japan is navigating an industry-wide FSA regulatory matter involving improper data extraction by seconded employees at partner agencies. Management characterized it as an industry issue with no observed impact on business results or sales. All seconded employees have returned to their positions and the practice has been discontinued. MetLife has a reporting order and is in confidential discussions with the FSA. Implication: Monitoring required; management's characterization as industry-wide and non-material is consistent with Q1 2026 commentary. PRU's Japan sales suspension (a separate, more severe issue) is not a read-through for MET.
• Ongoing — Sun Life Lawsuit: Sun Life issued a press release noting it can seek recourse from MetLife for approximately CAD 200M gross related to a class action lawsuit settlement. MetLife was not named a defendant in the class action and characterized Sun Life's claims as "baseless and misleading." Sun Life has taken no legal action to enforce the alleged indemnity claim. Implication: Monitoring required; management's characterization suggests limited financial risk, but the matter remains unresolved.
• Ongoing — MIM / PineBridge Integration: MetLife Investment Management completed its first fully integrated quarter with PineBridge in Q1 2026, with adjusted earnings of $47M (+68% YoY). Integration described as progressing better than anticipated, with a combined leadership team, new leveraged finance platform, and expanded alternatives. Pipeline described as constructive. Q1 saw ~$2B in institutional client outflows due to market volatility and integration dynamics; outflows stabilized in late Q1 and into April. Implication: Q2 MIM earnings trajectory and net flow trends will be closely watched as a key indicator of integration success.
• Ongoing — Private Credit / Balance Sheet Quality: At the Morgan Stanley Conference, management emphasized that MetLife's private fixed income portfolio is 95% investment grade, with middle-market direct lending representing less than 1% of the balance sheet and no BDC exposure. Credit characterized as "pretty stable" with any losses expected to be idiosyncratic rather than systemic. Implication: Positive for investor confidence in balance sheet quality amid broader private credit concerns.
• Ongoing — Capital Returns: MetLife repurchased ~$750M of common shares in Q1 2026 and ~$200M in April, with $1.1B remaining on the existing authorization. The Board declared a 4.4% increase in the common dividend per share. FY2026 share repurchases guided "generally in line with 2025" (~$3B). Implication: Continued strong capital return supports shareholder value; Q2 repurchase activity will be disclosed at earnings.

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by MET insiders were identified in the review period (June 1 – August 4, 2026). All Form 4 transactions identified were non-cash equity grants (transaction code "A") to directors as part of routine compensation, and one option exercise (code "M") by the Chief Risk Officer. There are no notable insider signals — the absence of open-market selling despite the stock's +20% rally since Q1 earnings is mildly constructive.

Source: SEC Form 4 Filings Database. Review period: June 1 – August 4, 2026. Only Form 4 (executed transactions) included. No open-market buys (Code P) or open-market sells (Code S) were identified for MET insiders during the review period. All transactions are equity grants (Code A) or option exercises (Code M), which are non-discretionary compensation-related transactions.

Assessment: Nothing stands out. The absence of open-market selling by executives or directors despite the stock's +20% rally since Q1 earnings is mildly constructive — insiders are not taking advantage of the elevated price to reduce holdings. No clustered buys or unusual sale patterns were identified.